ABITEC, Curapath form MOU on next-gen LNP delivery

ABITEC Corporation and Curapath signed a strategic memorandum of understanding to widen access to custom lipids, PEG-free shielding technologies and lipid nanoparticle formulation tools. The partnership is aimed at giving drug developers more options for vaccines, cell therapies and genetic medicines, especially for repeat-dosing applications.

Why it matters: - The agreement could broaden the design options available for lipid nanoparticle delivery systems, a core technology for vaccines, genetic medicines and other advanced therapeutics. - The collaboration is aimed at reducing dependence on PEG-lipids in applications where repeat dosing may benefit from alternative shielding approaches. - Developers may gain access to a more integrated set of lipid, shielding and manufacturing capabilities through one partnership.

What happened: - ABITEC Corporation and Curapath signed a strategic memorandum of understanding to expand access to high-purity custom lipids, PEG-free shielding technologies and advanced lipid nanoparticle formulation solutions. - The announcement was made Sept. 17, 2026, in Stockholm, Sweden. - ABITEC combines lipid chemistry and manufacturing expertise with Curapath’s PEG-free shielding polymer technologies and cGMP manufacturing capabilities under the agreement.

The details: - The companies said the MOU is designed to help developers build more flexible, fit-for-purpose LNP delivery systems. - ABITEC brings high-purity custom lipids to the collaboration. - Curapath contributes PEG-free shielding polymer technologies and cGMP manufacturing capabilities. - The partnership is intended to give customers broader formulation options for vaccines, cell therapies, genetic medicines and other advanced therapeutics. - ABITEC described the collaboration as addressing a key need in LNP development: more flexibility in lipid and shielding technologies. - Curapath said drug developers need integrated solutions to support complex therapeutic modalities. - Curapath said the combined effort expands the toolbox for innovators working across nucleic acid therapeutics, vaccines, cell therapies, biologics and other next-generation medicines. - ABITEC is a global leader in specialty lipids and surfactants serving pharmaceutical, nutraceutical, personal care, food and industrial applications. - ABITEC is part of ABF Ingredients, a division of Associated British Foods. - Curapath is a science-driven CDMO focused on the design, development and GMP manufacturing of advanced drug delivery systems. - Curapath works across polymer and lipid chemistry, nanoformulation and non-viral delivery technologies.

Between the lines: - The deal reflects a broader push in drug delivery toward formulations that can support more complex dosing and therapeutic profiles. - PEG-free shielding platforms are being positioned as an alternative where traditional PEG-lipid approaches may be less ideal. - The combination of chemistry, nanoformulation and manufacturing capabilities suggests both companies want to compete on end-to-end delivery development, not just individual components.

What's next: - ABITEC and Curapath are expected to use the MOU to support customers developing next-generation therapeutics and vaccines. - The companies did not announce a specific product launch, timeline or commercial terms. - More information about ABITEC and Curapath is available on the companies’ websites. - Curapath also shared its LinkedIn page for updates.

The bottom line: - The partnership gives developers a wider set of lipid nanoparticle tools as the field looks for more flexible and repeat-friendly delivery technologies.